## Francois Alhenc-Gelas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/850664/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kinins and Kinin Receptors in Cardiovascular and Renal Diseases. Pharmaceuticals, 2021, 14, 240.	3.8	13
2	Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication. Frontiers in Medicine, 2019, 6, 136.	2.6	16
3	Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice. Scientific Reports, 2017, 7, 9410.	3.3	10
4	Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade. Clinical Science, 2016, 130, 45-56.	4.3	19
5	Kinin Receptor Agonism Restores Hindlimb Postischemic Neovascularization Capacity in Diabetic Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 218-226.	2.5	19
6	Selective Kinin Receptor Agonists as Cardioprotective Agents in Myocardial Ischemia and Diabetes. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 23-30.	2.5	48
7	Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thrombosis and Haemostasis, 2013, 110, 476-483.	3.4	26
8	Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases. Current Pharmaceutical Design, 2011, 17, 2654-2662.	1.9	21
9	Tissue Kallikrein Is Essential for Invasive Capacity of Circulating Proangiogenic Cells. Circulation Research, 2011, 108, 284-293.	4.5	50
10	Critical Role of Tissue Kallikrein in Vessel Formation and Maturation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 657-664.	2.4	64
11	Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney International, 2009, 76, 395-403.	5.2	55
12	Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. European Journal of Heart Failure, 2008, 10, 343-351.	7.1	23
13	Partial Human Genetic Deficiency in Tissue Kallikrein Activity and Renal Calcium Handling. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 320-325.	4.5	19
14	Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 210-216.	2.5	46
15	Tissue Kallikrein–Deficient Mice Display a Defect in Renal Tubular Calcium Absorption. Journal of the American Society of Nephrology: JASN, 2005, 16, 3602-3610.	6.1	54
16	Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB Journal, 2005, 19, 1172-1174.	0.5	71
17	Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. Journal of Clinical Investigation, 2005, 115, 780-787.	8.2	64
18	Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. Journal of Clinical Investigation, 2005, 115, 780-787.	8.2	28

#	Article	IF	CITATIONS
19	Flow-Dependent Dilation Mediated by Endogenous Kinins Requires Angiotensin AT2Receptors. Circulation Research, 2004, 94, 1623-1629.	4.5	83
20	Cardiovascular Phenotypes of Kinin B2Receptor– and Tissue Kallikrein–Deficient Mice. Hypertension, 2002, 40, 90-95.	2.7	75
21	Loss-of-Function Polymorphism of the Human Kallikrein Gene with Reduced Urinary Kallikrein Activity. Journal of the American Society of Nephrology: JASN, 2002, 13, 968-976.	6.1	69
22	Negative Cooperativity in the Human Bradykinin B2Receptor. Journal of Biological Chemistry, 1998, 273, 1309-1315.	3.4	46
23	Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells. Prostaglandins, 1982, 24, 723-742.	1.2	137